BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/13/2014 7:02:00 PM | Browse: 1156 | Download: 1631
 |
Received |
|
2014-07-04 08:46 |
 |
Peer-Review Started |
|
2014-07-04 13:48 |
 |
To Make the First Decision |
|
2014-07-18 12:33 |
 |
Return for Revision |
|
2014-07-18 15:29 |
 |
Revised |
|
2014-07-19 02:55 |
 |
Second Decision |
|
2014-08-29 19:09 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2014-08-29 19:20 |
 |
Articles in Press |
|
2014-08-29 19:20 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2014-10-14 16:27 |
 |
Publish the Manuscript Online |
|
2014-12-13 19:01 |
Category |
Endocrinology & Metabolism |
Manuscript Type |
Minireviews |
Article Title |
Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes
|
Manuscript Source |
Invited Manuscript |
All Author List |
Nasser Mikhail |
Funding Agency and Grant Number |
|
Corresponding Author |
Nasser Mikhail, MD, MSc, Department of Medicine, Endocrine Division, OliveView-UCLA Medical Center, 14445 Olive View Dr, Sylmar, CA 91342,
United States. nmikhail@dhs.lacounty.gov
|
Key Words |
Type 2 diabetes; Canagliflozin dapagliflozin; Weight loss; Hypoglycemia; Chronic kidney disease; Genital infection |
Core Tip |
Sodium-glucose co-transporter type 2 inhibitors are recently approved drugs for type 2 diabetes with unique mechanism of action. In this minireview, the author provides a practical approach on how to select the best candidates for these drugs.
|
Publish Date |
2014-12-13 19:01 |
Citation |
Mikhail N. Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes. World J Diabetes 2014; 5(6): 854-859 |
URL |
http://www.wjgnet.com/1948-9358/full/v5/i6/854.htm |
DOI |
http://dx.doi.org/10.4239/wjd.v5.i6.854 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345